Genedrive Regulatory News (GDR)

For release: 24 February 2010

Notification of Interim Results (Half Yearly Results)

Epistem (AIM: EHP), the rapidly growing biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases will announce its half-yearly results for the six months ended 31 December 2009 on Tuesday, 9 March 2010.

An analysts' meeting will be held at 9.30am on Tuesday, 9 March 2010 at the offices of De Facto Communications, 330 High Holborn, London WC1V 7QD.

For further information, please contact: 

Epistem Plc

Matthew Walls CEO +44 161 606 7258 John Rylands Finance Director

Piper Jaffray Ltd.

Neil Mackison +44 203 142 8700 Corporate Broking: Jamie Adams

De Facto Communications

Mike Wort / Anna Dunphy +44 207 861 3838

Notes to Editors

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.